MannKind (MNKD)
(Delayed Data from NSDQ)
$5.70 USD
+0.09 (1.60%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $5.72 +0.02 (0.35%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
MNKD 5.70 +0.09(1.60%)
Will MNKD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MNKD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MNKD
MannKind (MNKD) Upgraded to Strong Buy: Here's Why
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
MNKD: What are Zacks experts saying now?
Zacks Private Portfolio Services
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Other News for MNKD
Buy Recommendation: MannKind’s Afrezza Shows Promising Efficacy and Market Growth Potential
MannKind announces 17-week results from INHALE-3 study
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
MannKind initiated with bullish view at Rodman & Renshaw
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions